Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676207 | 1.00 | KMT2A (0.55) | KMT2AGAATP53MAPTTSHR | |
| SCHEMBL27542302 | 0.85 | MAPT (0.56) | KMT2AGAATP53MAPTMEN1 | |
| SCHEMBL17032505 | 0.84 | KMT2A (0.50) | KMT2AGAATP53MAPTTSHR | |
| SCHEMBL262538 | 0.83 | AKR1C3 (0.59) | KMT2AGAATP53MAPTMEN1 | |
| SCHEMBL350868 | 0.83 | AKR1C3 (0.59) | KMT2AGAATP53MAPTMEN1 | |
| SCHEMBL15887351 | 0.83 | KMT2A (0.56) | KMT2AGAATP53MAPTMEN1 | |
| SCHEMBL6393416 | 0.83 | MAPT (0.55) | KMT2AGAATP53MAPTMEN1 | |
| SCHEMBL1343164 | 0.83 | AKR1C3 (0.59) | KMT2AGAATP53MAPTMEN1 | |
| SCHEMBL5676135 | 0.82 | TSHR (0.50) | KMT2AGAAMAPTTSHRMEN1 | |
| SCHEMBL2183429 | 0.81 | KMT2A (0.55) | KMT2AGAATP53MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024329-B1 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2013-07-31 | — | — | EP | disclosed |
| CN-101448784-B | (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them | DOMPE PHA R MA SPA RES & MFG | 2012-07-04 | — | — | CN | disclosed |
| US-7868046-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2011-01-11 | — | — | US | disclosed |
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | DOMPE' PHA.R.MA S.P.A. (IT) | 2010-06-17 | — | — | US | disclosed |
| US-7652169-B2 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | Dompe' Pha. R. Ma S.p.A. (IT) | 2010-01-26 | — | — | US | disclosed |
| CN-101448784-A | (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-06-03 | — | — | CN | disclosed |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2009-04-09 | — | — | US | disclosed |
| EP-2024329-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135080-A2 | (2R)-2-[(4-SULFONYL)AMINOPHENYL]PROPANAMIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA. S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152256-A1 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them | CCR2, CXCR2, CXCR4 | KMT2A 3845/4885GAA 4303/4885TP53 301/4885 |
| US-20090093530-A1 | (2R)-2-[4-Sulfonyl) Aminophenyl] Propanamides and Pharmaceutical Compositions Containing Them | CCR2, CXCR2, CXCR3 | KMT2A 3958/4885GAA 4128/4885TP53 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.